Polidocanol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Polidocanol: From Varicose Veins to Esophageal Varices with Bleeding
One-Sentence Summary
Polidocanol is an injectable sclerosing agent originally used to treat varicose veins. The TxGNN model predicts it may be effective for esophageal varices with bleeding, with 0 registered clinical trials and 20 publications (including 2 RCTs) currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Varicose veins (the US license record contains no indication text; taken from the knowledge-graph indication data) |
| Predicted New Indication | Esophageal varices with bleeding |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L1 (as assigned in the compiled data; inferred from literature titles only, see caveats below) |
| US Market Status | Cancelled only |
| Number of NDAs | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Based on known information, polidocanol is a sclerosing agent that damages the vascular endothelium and induces thrombosis and fibrosis of the vessel. This is the basis of its use in varicose veins.
Esophageal varices are also dilated veins. The same mechanism can be applied by injecting the drug into (intravariceal) or beside (paravariceal) the varix during endoscopy, which achieves hemostasis and obliterates the varix. Published studies describe this use in adults and in children and adolescents (for cardiac varices).
There are important caveats. The RCTs are old (1997 and 1999). Endoscopic band ligation is now generally preferred over sclerotherapy. Sclerotherapy carries known risks, including stricture, dysphagia and ulceration. One cohort reported stricture or dysphagia in 59% of patients (20 of 34). The evidence level was inferred from literature titles only and needs full-text verification.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9255525 | 1997 | RCT | Endoscopy | Prospective study of cyanoacrylate plus polidocanol versus polidocanol alone for bleeding esophageal varices in unselected cirrhotic patients |
| 10385713 | 1999 | RCT | Gastrointest Endosc | Ligation alone versus ligation plus sclerotherapy for bleeding esophageal varices |
| 2693076 | 1989 | Randomized trial | Endoscopy | Ethanolamine versus polidocanol in 50 cirrhotic patients; variceal eradication 81% vs 64% (not significant) |
| 3069543 | 1988 | Comparative study | Gastroenterol Clin Biol | Intravariceal polidocanol versus perivariceal quinine-urea in 74 patients with bleeding varices |
| 29473522 | 2017 | Review | Curr Clin Pharmacol | Evidence-based review of off-label polidocanol uses |
| 32517718 | 2020 | Systematic review | BMC Gastroenterol | Pooled rebleeding risk after cyanoacrylate treatment of gastroesophageal varices |
| 36509625 | 2023 | Cohort | Arch Pediatr | Paravariceal polidocanol sclerotherapy for cardiac varices in children and adolescents |
| 10434360 | 1999 | Comparative study | J UOEH | Band ligation (101 patients) versus paravariceal polidocanol (40 patients); hemostasis 100% in both, rebleeding 40.0% vs 29.6% |
| 6609102 | 1984 | Cohort (adverse events) | Gut | Stricture or dysphagia in 59% of 34 patients after repeated polidocanol sclerotherapy |
| 20737152 | 2011 | Cohort | Eur Radiol | Polidocanol foam for balloon-occluded retrograde transvenous obliteration of gastric fundal varices |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA021201 (cancelled) | Asclera (Methapharm, Inc) | Injection, solution | Not stated in the available record |
Safety Considerations
- Safety signal from the literature: Sclerotherapy with polidocanol has been associated with esophageal stricture and dysphagia (59% in one 34-patient cohort), and may aggravate portal hypertension by suppressing portosystemic shunts.
- Drug interactions: No interaction records were found.
Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted indication has a plausible mechanism and multiple published studies, including two RCTs. However, these are old, no clinical trials are registered, and band ligation is now the preferred endoscopic treatment. The only US license is cancelled, which limits practical availability.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- Full-text verification of the RCTs and the evidence level
- A comparison against current standard care (band ligation, beta-blockers)
- A plan for stricture, dysphagia and ulceration monitoring
- Clarification of product availability, given the cancelled US license
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.